By SPC News Staff
The U.S. Supreme Court denied the petition of Sandoz to review the Federal Circuit’s July 2020 decision concerning its biosimilar etanercept-szzs (Erelzi) for reference medicine etanercept (Enbrel, Amgen). The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen’s patents.
Specifically, the appellate court affirmed an Aug. 9, 2019 decision by the United States District Court for the District of New Jersey that had upheld the validity